San Diego-centered Viking Therapeutics marked by itself as a serious competitor from the weight loss drug sector in February soon after revealing promising information from a mid-stage trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when supplied as being a weekly injection As well as in March